SLIDE 1 HCV Treatment Rate in Select European Countries in 2004–2010
April 25, 2013
- H. Razavi, C. Estes, K. Pasini, E. Gower, S. Hindman
SLIDE 2 Disclosure:
- The Center for Disease Analysis has received funding or grants from
AbbVie, Boehringer Ingelheim, Gilead, Merck, Novartis, and Vertex
- The funding for this work was provided by the Center for Disease
Analysis
2
SLIDE 3 Background
- The emergence of new direct acting antiviral (DAA) therapies will, most likely,
lead to increase in the number of treated HCV patients. H th i l k f hi t i l d t th b f ti t t t d
- However, there is a lack of historical data on the number of patients treated.
- Objective: Quantify the number of patients treated and the treatment rate for 22
European countries: North & Western
» Austria » Belgium
Southern Europe
» Greece » Italy
Eastern Europe
» Czech Republic » Hungary » Denmark » Finland » France » Germany » Portugal » Spain » Poland » Romania » Russia » Slovakia » Germany » Ireland » Netherlands » Norway » Slovakia
3
» Sweden » Switzerland » UK
SLIDE 4 Methodology
- The study was limited to 22 European countries where reliable data was
available.
- The annual number of pegylated interferon (alpha & beta) units sold was
gathered by country.
- The number of units were adjusted for:
» Uses in non-HCV indications – including treatment of hepatitis B virus (HBV) infection. » Under-reporting – used comparisons of sales channels (hospital and retail) and national data reporting total treated population.
- The average number of units per patient per year was calculated based upon:
» Country-specific genotype distributions » Average duration of treatment by genotype » Average Peg/Riba therapy persistence
- The annual number of treated patients was estimated using the adjusted units
sold and the average number of units per patient per year.
4
g p p p y
SLIDE 5 Example: France
56% of Pts are G1 29% of Pts are G2/3 15% of Pts are G4/Other 48 Weeks
24 Weeks
48 Weeks
Average #
439,200 Units Sold Average #
per Pt 41.0 Use in HBV Persistence 85% Units per Patient 34.9 Use in HBV (-10%)
5
11,325 Patients Treated
SLIDE 6
Total Number of Viremic HCV Cases – 2010 (000)
2 100 2,500 (000) 2,100 1 500 2,000 ases in 2010 ( 1,500 1 000 1,500 remic HCV Ca 600 540 450 500 1,000 Number of Vir 230 210 190 120 120 120 70 70 50 40 40 40 30 30 20 20 10 Total N
6
Alberti A, Negro F, The global burden of hepatitis C virus infection. Liver Int 2011; 31, Suppl 2: 1-80
SLIDE 7
Viremic HCV prevalence, in these 22 countries, was ~6.7 million with over 50% in Russia and Italy
Italy Other y 1,500,000 23% Countries 3,000,000 45% Russia 2,100,000 32%
7
32%
SLIDE 8
Annual Number of Treated HCV Patients in 2004 & 2010
25,000 2004 2010 20,000 Patients 10 000 15,000 r of Treated P 5,000 10,000 nnual Numbe An
8
SLIDE 9
Results: Treatment Rate in 2010
6 7%
7 0% 8.0%
6.7%
5 0% 6.0% 7.0% ate
4.3% 4.3% 3.5% 3.4% 3.0% 3.0% 2 7%
3 0% 4.0% 5.0% Treatment Ra
2.7% 2.6% 2.3% 2.2% 2.1% 1.5% 1.5% 1.1% 1.1% 1.0% 1.0% 0.8% 0 7%
1 0% 2.0% 3.0% T
0.8% 0.7% 0.4% 0.3%
0.0% 1.0%
9
SLIDE 10
Results: Treatment by Region 2004-2010
4.5% North & Western Europe Southern Europe Eastern Europe 3.5% 4.0% 2.5% 3.0%
atment Rate
1.5% 2.0%
Trea
0.5% 1.0%
10
0.0%
2004 2005 2006 2007 2008 2009 2010
SLIDE 11 Key Insights
- There was more than an order of magnitude difference in treatment rate
among European countries
» Lowest treatment rate was in Eastern Europe » Highest treatment rate was in Western Europe
- Treatment rate in Eastern Europe increased between 2004-2010 but
remained well below other countries in the region
- In Western Europe, there were signs of patients being warehoused
p , g p g starting in 2008
- In Italy & Russia, the high number of treated patients is small relative to
the overall HCV prevalence the overall HCV prevalence
- France has the highest treatment rate in Europe (and globally)
11
